A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan

References

• Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol 2009;44:518–34.
   PubMed Web of Science ®Google Scholar
• Armstrong D. Systematic review: persistence and severity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;28:841–53.
   PubMed Web of Science ®Google Scholar
• Nagahara A, Hojo M, Asaoka D, Watanabe S. Maintenance therapy of gastroesophageal reflux disease. Clin J Gastroenterol 2010;3:61–8.
   PubMedGoogle Scholar
• Tsuzuki T, Okada H, Kawahara Y, Takenaka R, Nasu J, Ishioka H, et al. Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol 2011;17:1480–7.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Hongo M; Maintenance Study Group. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern Med 2011;50:179–88.
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Hongo M; Maintenance Study Group. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. J Gastroenterol 2010;45:1193–200.
   PubMed Web of Science ®Google Scholar
• Yoshida N, Kamada K, Tomatsuri N, Suzuki T, Takagi T, Ichikawa H, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci 2010;55:3393–8.
   PubMed Web of Science ®Google Scholar
• Jiang YX, Chen Y, Kong X, Tong YL, Xu SC. Maintenance treatment of mild gastroesophageal reflux disease with proton pump inhibitors taken on-demand: a meta-analysis. Hepatogastroenterology 2013;60:1077–82.
   PubMedGoogle Scholar
• Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 2006;41:95–9.
   PubMed Web of Science ®Google Scholar
• Sakurai K, Nagahara A, Inoue K, Akiyama J, Mabe K, Suzuki J, et al. Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). BMC Gastroenterol 2012;12:42.
   PubMed Web of Science ®Google Scholar
• Cibor D, Ciećko-Michalska I, Owczarek D, Szczepanek M. Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms—a pilot study. Adv Med Sci 2006;51:336–9.
   PubMedGoogle Scholar
• Morgan DG, O'Mahony MF, O'Mahony WF, Roy J, Camacho F, Dinniwell J, et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can J Gastroenterol 2007;21:820–6.
   PubMed Web of Science ®Google Scholar
• Tepes B, Stabuc B, Kocijancic B, Ivanusa M. Maintenance therapy of gastroesophageal reflux disease patients with omeprazole. Hepatogastroenterology 2009;56:67–74.
   PubMedGoogle Scholar
• Tsai HH, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004;20:657–65.
   PubMed Web of Science ®Google Scholar
• Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007:CD003244.
   PubMed Web of Science ®Google Scholar
• Bredenoord AJ. Mechanisms of reflux perception in gastroesophageal reflux disease: a review. Am J Gastroenterol 2012;107:8–15.
   PubMed Web of Science ®Google Scholar
• Oguro M, Koike M, Ueno T, Asaoka D, Mori H, Nagahara A, et al. Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease. J Gastroenterol 2011;46:629–38.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Bortolotti M, Fabbri A, Areni A, Cenacchi G, Scialpi C, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005;100:537–42.
   PubMed Web of Science ®Google Scholar
• Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, et al. Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998:41–9.
   PubMedGoogle Scholar
• Hongo M, Kinoshita Y, Shimozuma K, Kumagai Y, Sawada M, Nii M. Psychometric validation of the Japanese translation of the Quality of Life in Reflux and Dyspepsia questionnaire in patients with heartburn. J Gastroenterol 2007;42:807–15.
   PubMed Web of Science ®Google Scholar
• Hirata K, Suzuki H, Matsuzaki J, Masaoka T, Saito Y, Nishizawa T, et al. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy. J Clin Biochem Nutr 2013;52:172–8.
   PubMed Web of Science ®Google Scholar
• Nagahara A, Hojo M, Asaoka D, Sasaki H, Oguro M, Mori H, et al. Clinical feature of asymptomatic reflux esophagitis in patients who underwent upper gastrointestinal endoscopy. J Gastroenterol Hepatol 2012;27:53–7.
   PubMed Web of Science ®Google Scholar
• Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131–7.
   PubMed Web of Science ®Google Scholar
• Miwa H, Minoo T, Hojo M, Yaginuma R, Nagahara A, Kawabe M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther 2004;20:112–17.
   PubMed Web of Science ®Google Scholar
• Nagahara A, Miwa H, Minoo T, Hojo M, Kawabe M, Osada T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol 2006;40:891–5.
   PubMed Web of Science ®Google Scholar
• Miwa H, Inoue K, Ashida K, Kogawa T, Nagahara A, Yoshida S, et al. Japan TREND study group. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;33:323–32.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2011;33:213–24.
   PubMed Web of Science ®Google Scholar
• Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, et al. ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 2007;26:69–77.
   PubMed Web of Science ®Google Scholar
• Weijenborg PW, Cremonini F, Smout AJ, Bredenoord AJ. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012;24:747–57, e350.
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005;40:275–85.
   PubMed Web of Science ®Google Scholar